Xilio Therapeutics (XLO) Accounts Payables (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 53.23% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 53.23% YoY), and the FY2025 full-year result was $3.2 million, up 23.08% from the prior year.
• Accounts Payables declined to $1.1 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.1 million in Q2 2025 to a low of $746000.0 in Q1 2024.
• A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables tumbled 66.4% in 2023 and jumped 224.13% in 2025, its largest moves.
• Tracing XLO's Accounts Payables over 5 years: stood at $3.1 million in 2022, then slumped by 66.4% to $1.0 million in 2023, then surged by 145.14% to $2.6 million in 2024, then increased by 23.08% to $3.2 million in 2025, then sank by 66.41% to $1.1 million in 2026.
• Business Quant data shows XLO's Accounts Payables at $1.1 million in Q1 2026, $3.2 million in Q4 2025, and $2.3 million in Q3 2025.